FDA Policy on “Off Label” Use Causes First Amendment Fight

August 19, 2015

After being accused of “misbranding” their product, Amarin Pharma, a pharmaceutical company that manufacturers Vascepa, a cardiovascular health drug, recently challenged the FDA after promoting the product for an “off label” use, according to the Agency.

“Off label”, which is defined as “the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration,” can apply to both prescription and over the counter (OTC) products. If a company desires to promote their product for a something that is not the FDA-approved intended use, then additional clinical trials must be conducted and approval must be obtained before promoting the use to doctors.

As such, Amarin conducted an FDA-approved study, which showed that the drug was effective in treating the off label use, but the agency denied approval. Amarin is now claiming that FDA’s rules regarding off label promotion are unfair and violate their right to free-speech, as stated in the First Amendment. The outcome of this statement? The company asked the district court to block any enforcement action, and the judge agreed, saying FDA’s rules and regulations regarding off-label marketing and promotion have too many incongruities.

However, while the First Amendment does protect speech that is true, it does not support or protect fraudulent speech. In the past, there have been courts that have rejected challenges to FDA’s off-label promotion requirements, but they have typically involved charges of fraud for mislesding doctors and the agency about the use of the product(s) in question.

It is more than likely that the FDA will appeal the decision of the district court, taking it to the US Court of Appeals for the Second Circuit, however we will just have to wait and see what their next step is and what results from those actions.

Making sure you are only promoting your FDA-approved product in ways that comply with the intended use(s) can be challenging and can sometimes get a little tricky. We have experience helping our clients comply with the FDA’s rules and regulations regarding off label promotion and advertisement of their products. For more info on how we can help you ensure and maintain compliance, please contact us



Agency Alerts General Regulatory

August 19, 2015

FDA Finalizes the Establishment of the Patient Engagement Advisory Committee

In October 2015 the FDA established its first ever Patient Engagement Advisory Committee (PEAC). This was done as part of the Agency’s 'patient-centric' approach, under which FDA is attempting to...

Read More
Cleaning Validation Life Science Consulting

August 19, 2015

Personalized Medicine – How Will the Batch Size Change Our Lives?

Hardly a week goes by without the announcement of a new scientific break-through in science and medicine that promises safer, more efficacious and personalized medicine.  Where are all these...

Read More
General Regulatory Regulatory Sciences

August 19, 2015

FDA Study Finds Lower Risk of Lung Cancer Among Menthol Smokers

In March 2011, the Tobacco Products Scientific Advisory Committee released a report on the impact of menthol on public health.  Based on the committee’s review of all available evidence, they...

Read More